Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial. ITM Isotope ...

Learn about VE303, a potential first-in-class Live Biotherapeutic Product for preventing recurrent Clostridioides difficile ...

Discover the groundbreaking AI-based platform that designs peptides to target and destroy previously 'undruggable' ...

Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients. Coherus BioSciences announced the final data from ...

Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients. The CF AMR Syndicate, which combines expertise from various sectors ...

Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients.

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease. Fostamatinib, marketed as TAVALISSE ® in the US for chronic ...

Cancer Research UK, Cytovation, and the Norwegian Cancer Society have teamed up to advance the treatment of adrenocortical carcinoma (ACC). The collaboration will support the Phase II clinical trial ...